Literature DB >> 7082499

Electrophysiological effects of sotalol--just another beta blocker?

A W Nathan, K J Hellestrand, R S Bexton, D E Ward, R A Spurrell, A J Camm.   

Abstract

The electrophysiological effects of intravenous sotalol hydrochloride (0.4 mg/kg) were assessed in 24 patients, including 13 with the Wolff-Parkinson-White syndrome, undergoing routine electrophysiological study. Fifteen to 30 minutes after sotalol administration there was a significant increase in sinus cycle length and in sinus node recovery time. There was a small increase in the AH interval, but the HV interval was unchanged. The QT and JT intervals, measured during sinus rhythm, were both increased. The atrial, ventricular, and atrioventricular nodal effective refractory periods were all prolonged, as was the atrioventricular nodal functional refractory period. In 13 patients with ventricular pre-excitation there was an increase of the accessory pathway anterograde and retrograde effective refractory periods. In 12 of these 13 sotalol was given during atrioventricular re-entrant tachycardia, resulting in termination in five. Tachycardia cycle length increased in all patients, with the major effect being in the atrioventricular direction. Though some of the effects seen in these patients are consistent with the beta adrenergic antagonist properties of sotalol, the effect on atrial, ventricular, and accessory pathway effective refractory periods and on ventricular repolarisation is not typical of that observed with other beta blockers but may be the result of lengthening of the action potential duration. These findings suggest that sotalol may be a more versatile antiarrhythmic agent than other beta receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082499      PMCID: PMC481176          DOI: 10.1136/hrt.47.6.515

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  30 in total

1.  Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue.

Authors:  H C Strauss; J T Bigger; B F Hoffman
Journal:  Circ Res       Date:  1970-06       Impact factor: 17.367

2.  The effects of cycle length on cardiac refractory periods in man.

Authors:  P Denes; D Wu; R Dhingra; R J Pietras; K M Rosen
Journal:  Circulation       Date:  1974-01       Impact factor: 29.690

3.  Measurements of sinus impulse conduction from electrogram of bundle of His.

Authors:  S Bekheit; J G Murtagh; P Morton; E Fletcher
Journal:  Br Heart J       Date:  1971-09

Review 4.  Perspectives in adrenergic beta-receptor blockade.

Authors:  J D Fitzgerald
Journal:  Clin Pharmacol Ther       Date:  1969 May-Jun       Impact factor: 6.875

5.  Sotalol: a new, safe beta adrenergic receptor blocking agent.

Authors:  W S Frankl; L A Soloff
Journal:  Am J Cardiol       Date:  1968-08       Impact factor: 2.778

6.  Localization of A-V conduction defects in man by recording of the His bundle electrogram.

Authors:  O S Narula; L S Cohen; P Samet; J W Lister; B Scherlag; F J Hildner
Journal:  Am J Cardiol       Date:  1970-02       Impact factor: 2.778

7.  Patterns of atrioventricular conduction in the human heart.

Authors:  A L Wit; M B Weiss; W D Berkowitz; K M Rosen; C Steiner; A N Damato
Journal:  Circ Res       Date:  1970-09       Impact factor: 17.367

8.  [Effect of amiodarone on cardiac rhythm and electrocardiograms].

Authors:  J Facquet; M Nivet; Y Grosgogeat; P Alhomme; J Vachon
Journal:  Therapie       Date:  1970 Mar-Apr       Impact factor: 2.070

9.  Evaluation of sino-atrial node function in man by overdrive suppression.

Authors:  W Mandel; H Hayakawa; R Danzig; H S Marcus
Journal:  Circulation       Date:  1971-07       Impact factor: 29.690

10.  A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474.

Authors:  B N Singh; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

View more
  11 in total

1.  Effect of long term treatment with metoprolol and sotalol on ventricular repolarisation measured by use of transoesophageal atrial pacing.

Authors:  C Blomström-Lundqvist; M Dohnal; I Hirsch; A Lindblad; A Hjalmarson; S B Olsson; N Edvardsson
Journal:  Br Heart J       Date:  1986-02

2.  Successful termination of combined rapid atrial flutter/fibrillation and ventricular tachycardia by intravenous sotalol.

Authors:  D R Ramsdale; C Peterson
Journal:  Postgrad Med J       Date:  1987-07       Impact factor: 2.401

Review 3.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

4.  Efficacy of oral sotalol in reentrant ventricular tachycardia.

Authors:  I W Obel; R Jardine; B Haitus; R N Millar
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 5.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Cellular electrophysiological effects of D- and DL-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity.

Authors:  T J Campbell
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

7.  Sotalol, hypokalaemia, syncope, and torsade de pointes.

Authors:  J K McKibbin; W A Pocock; J B Barlow; R N Millar; I W Obel
Journal:  Br Heart J       Date:  1984-02

Review 8.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 9.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Preliminary clinical pharmacological studies of S3341, a new hypotensive agent, and comparison with clonidine in normal males.

Authors:  K Weerasuriya; E Shaw; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.